Detection of circulating cell-free HPV DNA of 13 HPV types for patients with cervical cancer as potential biomarker to monitor therapy response and to detect relapse
© 2023. The Author(s)..
BACKGROUND: HPV-related cervical cancer (CC) is the fourth most frequent cancer in women worldwide. Cell-free tumour DNA is a potent biomarker to detect treatment response, residual disease, and relapse. We investigated the potential use of cell-free circulating HPV-DNA (cfHPV-DNA) in plasma of patients with CC.
METHODS: cfHPV-DNA levels were measured using a highly sensitive next-generation sequencing-based approach targeting a panel of 13 high-risk HPV types.
RESULTS: Sequencing was performed in 69 blood samples collected from 35 patients, of which 26 were treatment-naive when the first liquid biopsy sample was retrieved. cfHPV-DNA was successfully detected in 22/26 (85%) cases. A significant correlation between tumour burden and cfHPV-DNA levels was observed: cfHPV-DNA was detectable in all treatment-naive patients with advanced-stage disease (17/17, FIGO IB3-IVB) and in 5/9 patients with early-stage disease (FIGO IA-IB2). Sequential samples revealed a decrease of cfHPV-DNA levels in 7 patients corresponding treatment response and an increase in a patient with relapse.
CONCLUSIONS: In this proof-of-concept study we demonstrated the potential of cfHPV-DNA as a biomarker for therapy monitoring in patients with primary and recurrent CC. Our findings facilitate the development of a sensitive and precise, non-invasive, inexpensive, and easily accessible tool in CC diagnosis, therapy monitoring and follow-up.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:128 |
|---|---|
| Enthalten in: |
British journal of cancer - 128(2023), 11 vom: 27. Juni, Seite 2097-2103 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mittelstadt, Suzana [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biomarkers |
|---|
| Anmerkungen: |
Date Completed 25.05.2023 Date Revised 29.05.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41416-023-02233-x |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM354784552 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM354784552 | ||
| 003 | DE-627 | ||
| 005 | 20231226062948.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41416-023-02233-x |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1182.xml |
| 035 | |a (DE-627)NLM354784552 | ||
| 035 | |a (NLM)36973448 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mittelstadt, Suzana |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Detection of circulating cell-free HPV DNA of 13 HPV types for patients with cervical cancer as potential biomarker to monitor therapy response and to detect relapse |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.05.2023 | ||
| 500 | |a Date Revised 29.05.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s). | ||
| 520 | |a BACKGROUND: HPV-related cervical cancer (CC) is the fourth most frequent cancer in women worldwide. Cell-free tumour DNA is a potent biomarker to detect treatment response, residual disease, and relapse. We investigated the potential use of cell-free circulating HPV-DNA (cfHPV-DNA) in plasma of patients with CC | ||
| 520 | |a METHODS: cfHPV-DNA levels were measured using a highly sensitive next-generation sequencing-based approach targeting a panel of 13 high-risk HPV types | ||
| 520 | |a RESULTS: Sequencing was performed in 69 blood samples collected from 35 patients, of which 26 were treatment-naive when the first liquid biopsy sample was retrieved. cfHPV-DNA was successfully detected in 22/26 (85%) cases. A significant correlation between tumour burden and cfHPV-DNA levels was observed: cfHPV-DNA was detectable in all treatment-naive patients with advanced-stage disease (17/17, FIGO IB3-IVB) and in 5/9 patients with early-stage disease (FIGO IA-IB2). Sequential samples revealed a decrease of cfHPV-DNA levels in 7 patients corresponding treatment response and an increase in a patient with relapse | ||
| 520 | |a CONCLUSIONS: In this proof-of-concept study we demonstrated the potential of cfHPV-DNA as a biomarker for therapy monitoring in patients with primary and recurrent CC. Our findings facilitate the development of a sensitive and precise, non-invasive, inexpensive, and easily accessible tool in CC diagnosis, therapy monitoring and follow-up | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Cell-Free Nucleic Acids |2 NLM | |
| 650 | 7 | |a Circulating Tumor DNA |2 NLM | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 700 | 1 | |a Kelemen, Olga |e verfasserin |4 aut | |
| 700 | 1 | |a Admard, Jakob |e verfasserin |4 aut | |
| 700 | 1 | |a Gschwind, Axel |e verfasserin |4 aut | |
| 700 | 1 | |a Koch, André |e verfasserin |4 aut | |
| 700 | 1 | |a Wörz, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a Oberlechner, Ernst |e verfasserin |4 aut | |
| 700 | 1 | |a Engler, Tobias |e verfasserin |4 aut | |
| 700 | 1 | |a Bonzheim, Irina |e verfasserin |4 aut | |
| 700 | 1 | |a Staebler, Annette |e verfasserin |4 aut | |
| 700 | 1 | |a Weidner, Nicola |e verfasserin |4 aut | |
| 700 | 1 | |a Stubenrauch, Frank |e verfasserin |4 aut | |
| 700 | 1 | |a Iftner, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Riess, Olaf |e verfasserin |4 aut | |
| 700 | 1 | |a Schroeder, Christopher |e verfasserin |4 aut | |
| 700 | 1 | |a Kommoss, Stefan |e verfasserin |4 aut | |
| 700 | 1 | |a Ossowski, Stephan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t British journal of cancer |d 1947 |g 128(2023), 11 vom: 27. Juni, Seite 2097-2103 |w (DE-627)NLM000027537 |x 1532-1827 |7 nnns |
| 773 | 1 | 8 | |g volume:128 |g year:2023 |g number:11 |g day:27 |g month:06 |g pages:2097-2103 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41416-023-02233-x |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 128 |j 2023 |e 11 |b 27 |c 06 |h 2097-2103 | ||